Literature DB >> 30001568

DEGUM, ÖGUM, SGUM and FMF Germany Recommendations for the Implementation of First-Trimester Screening, Detailed Ultrasound, Cell-Free DNA Screening and Diagnostic Procedures.

Peter Kozlowski1, Tilo Burkhardt2, Ulrich Gembruch3, Markus Gonser4, Christiane Kähler5, Karl-Oliver Kagan6, Constantin von Kaisenberg7, Philipp Klaritsch8, Eberhard Merz9, Horst Steiner10, Sevgi Tercanli11, Klaus Vetter12, Thomas Schramm13.   

Abstract

First-trimester screening between 11 + 0 and 13 + 6 weeks with qualified prenatal counseling, detailed ultrasound, biochemical markers and maternal factors has become the basis for decisions about further examinations. It detects numerous structural and genetic anomalies. The inclusion of uterine artery Doppler and PlGF screens for preeclampsia and fetal growth restriction. Low-dose aspirin significantly reduces the prevalence of severe preterm eclampsia. Cut-off values define groups of high, intermediate and low probability. Prenatal counseling uses detection and false-positive rates to work out the individual need profile and the corresponding decision: no further diagnosis/screening - cell-free DNA screening - diagnostic procedure and genetic analysis. In pre-test counseling it must be recognized that the prevalence of trisomy 21, 18 or 13 is low in younger women, as in submicroscopic anomalies in every maternal age. Even with high specificities, the positive predictive values of screening tests for rare anomalies are low. In the general population trisomies and sex chromosome aneuploidies account for approximately 70 % of anomalies recognizable by conventional genetic analysis. Screen positive results of cfDNA tests have to be proven by diagnostic procedure and genetic diagnosis. In cases of inconclusive results a higher rate of genetic anomalies is detected. Procedure-related fetal loss rates after chorionic biopsy and amniocentesis performed by experts are lower than 1 to 2 in 1000. Counseling should include the possible detection of submicroscopic anomalies by comparative genomic hybridization (array-CGH). At present, existing studies about screening for microdeletions and duplications do not provide reliable data to calculate sensitivities, false-positive rates and positive predictive values. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30001568     DOI: 10.1055/a-0631-8898

Source DB:  PubMed          Journal:  Ultraschall Med        ISSN: 0172-4614            Impact factor:   6.548


  8 in total

Review 1.  Pregnancy and Autoimmune Disease.

Authors:  Waltraut Maria Merz; Rebecca Fischer-Betz; Kerstin Hellwig; Georg Lamprecht; Ulrich Gembruch
Journal:  Dtsch Arztebl Int       Date:  2022-03-04       Impact factor: 8.251

2.  Audit of the first > 7500 noninvasive prenatal aneuploidy tests in a Swiss genetics center.

Authors:  Anahita Bajka; Michael Bajka; Fabian Chablais; Tilo Burkhardt
Journal:  Arch Gynecol Obstet       Date:  2021-09-17       Impact factor: 2.493

Review 3.  Potential of Next-Generation Sequencing in Noninvasive Fetal Molecular Blood Group Genotyping.

Authors:  Sandra Wienzek-Lischka; Sandy Bachmann; Vanessa Froehner; Gregor Bein
Journal:  Transfus Med Hemother       Date:  2020-01-20       Impact factor: 3.747

4.  False-positives and false-negatives in non-invasive prenatal testing (NIPT): what can we learn from a meta-analyses on > 750,000 tests?

Authors:  Thomas Liehr
Journal:  Mol Cytogenet       Date:  2022-08-19       Impact factor: 1.904

5.  First Trimester Screening - Current Status and Future Prospects After Introduction of Non-invasive Prenatal Testing (NIPT) at a Tertiary Referral Center.

Authors:  Adeline Walter; Corinna Simonini; Ulrich Gembruch; Anne Flöck; Brigitte Strizek; Annegret Geipel
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-09-06       Impact factor: 2.754

Review 6.  Non-Invasive Prenatal Testing beyond Trisomies.

Authors:  Ioan Dumitru Suciu; Oana Daniela Toader; Slavyana Galeva; Lucian Pop
Journal:  J Med Life       Date:  2019 Jul-Sep

7.  Analysis of cell-free DNA in a consecutive series of 13,607 routine cases for the detection of fetal chromosomal aneuploidies in a single center in Germany.

Authors:  Heike Borth; Anna Teubert; Ralf Glaubitz; Sarah Knippenberg; Nargül Kutur; Thomas Winkler; Bernd Eiben
Journal:  Arch Gynecol Obstet       Date:  2020-11-05       Impact factor: 2.344

Review 8.  Antenatal screening for chromosomal abnormalities.

Authors:  Karl Oliver Kagan; Jiri Sonek; Peter Kozlowski
Journal:  Arch Gynecol Obstet       Date:  2022-03-13       Impact factor: 2.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.